Moleculin Biotech Inc
NASDAQ:MBRX
Moleculin Biotech Inc
NASDAQ:MBRX
Price:
2.32
USD
4.04%
Market Closed
Market Cap:
$11.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Moleculin Biotech Inc
NASDAQ:MBRX
|
US |
|
Pexip Holding ASA
F:4W9
|
NO |
|
G
|
Graft Polymer UK PLC
LSE:GPL
|
UK |
|
Hangzhou Coco Healthcare Products Co Ltd
SZSE:301009
|
CN |
|
M
|
MUI Properties Bhd
KLSE:MUIPROP
|
MY |
|
Coda Octopus Group Inc
NASDAQ:CODA
|
US |
|
G
|
Guangdong Rongtai Industry Co Ltd
SSE:600589
|
CN |
|
P
|
Pinar Su ve Icecek Sanayi ve Ticaret AS
IST:PINSU.E
|
TR |
|
Bastei Luebbe AG
XETRA:BST
|
DE |
|
Capitaland Investment Ltd
OTC:CLILF
|
SG |
|
Care REIT PLC
LSE:CRT
|
UK |
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
US |
|
Cavitation Technologies Inc
OTC:CVAT
|
US |
|
DFS Furniture PLC
LSE:DFS
|
UK |
|
M
|
Malaysian Bulk Carriers Bhd
KLSE:MAYBULK
|
MY |
|
Nedap NV
AEX:NEDAP
|
NL |
|
PRT Company Ltd
ASX:PRT
|
AU |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of MBRX.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MBRX
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
MBRX Competitors Multiples
Moleculin Biotech Inc Competitors
Moleculin Biotech Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Moleculin Biotech Inc
NASDAQ:MBRX
|
11.4m USD | 0 | -0.2 | -0.2 | -0.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD | 6 | 88.2 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD | 5.9 | 20.4 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
